News | 27 December 2012
Celator Pharmaceuticals has commenced patient enrollment in the phase-III study of CPX-351 in untreated high-risk acute myeloid leukemia (AML). The open-label trial is designed to assess CPX-351 (cytarabine:daunorubicin) liposome injection compared to ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)